Investigation of a family following fulminant malignant hyperthermia

Journal of Clinical Neuromuscular Disease

Volumn 5, Issue 3, 2004, Pages 122-128

  Snoeck, Marc ^a   Sengers, Rob ^b   Iles, David ^c   ter Laak, Henk ^b   Robinson, Rachel ^d   Padberg, George ^b  

^a CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^b RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^c UNIVERSITY OF LEEDS   (United Kingdom)

^d ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Diagnosis; Family screening; In vitro contracture test; Malignant hyperthermia

Indexed keywords

ANESTHETIC AGENT; CALCIUM; CREATINE KINASE; GENOMIC DNA; HALOTHANE; SUXAMETHONIUM;

ADULT; AGED; CALCIUM CELL LEVEL; CELL CULTURE; CHROMOSOME 19Q; CLINICAL ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DEATH; DIAGNOSTIC PROCEDURE; DISEASE PREDISPOSITION; DNA ISOLATION; DRUG SURVEILLANCE PROGRAM; ENZYME BLOOD LEVEL; FAMILY HISTORY; FEMALE; GENE LOCUS; GENERAL ANESTHESIA; GENETIC ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LINKAGE ANALYSIS; MALE; MALIGNANT HYPERTHERMIA; MUSCLE CELL; MUSCLE CONTRACTURE; MUTATIONAL ANALYSIS; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; SKELETAL MUSCLE;

EID: 4644301668     PISSN: 15220443     EISSN: None     Source Type: Journal    
DOI: 10.1097/00131402-200403000-00003     Document Type: Review

References (22)

1. Denborough MA, Foster JFA, Lovell RRH, et al. Anaesthetic death in a family. Br J Anaesth. 1962;34: 395-396.
2. Kalow W, Britt BA, Terreau MH, et al. Metabolic error of muscle metabolism after recovery from malignant hyperthermia. Lancet. 1970;ii:895-898.
3. Ellis FR, Harriman DGF, Keaney NP, et al. Halothane-induced muscle contracture as a cause of hyperpyrexia. Br J Anaesth. 1971;43:721-722.
4. European MH Group. A protocol for the investigation of malignant hyperthermia (MH) susceptibility. BrJ Anaesth. 1984;56:1267-1269.
5. Larach MG, for the North American Malignant Hyperthermia Group. Standardisation of the caffeine halothane muscle contracture test. Anaesth Analg. 1989;69:511-515.
6. McCarthy TV, Healy JMS, Heffron JJA, et al. Localisation of the malignant hyperthermia susceptibility locus to human chromosome 19q12-13.2. Nature. 1990;343:562-564.
7. Miller SA, Dykes DD, Polesky HE. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215.
8. Quane KA, Healy JMS, Keating KE, et al. Mutations in the ryanodine receptor gene in central core disease and malignant hyperthermia. Nat Genet. 1993;5: 51-55.
9. Snoeck MMJ, Oosterhof A, Tangerman A, et al. Halothane-induced calcium release in cultured human skeletal muscle cells from a family susceptible to MH, with an unidentified mutation in chromosome 19. Anesthesiology. 2002;97:272-274.
10. Hildebrandt F, Pohlman A, Omran H. LODVIEW: a computer program for the graphical evaluation of lod score results in exclusion mapping of human disease genes. Comput Biomed Res. 1993;26:592-559.
11. Urwyler A, Deufel T, McCarthy T, et al. Guidelines for molecular genetic detection of susceptibility to malignant hyperthermia. Br J Anaesth. 2001;86: 283-287.
12. Larach M, Localio A, Allen G, et al. A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology. 1994;80:771-779.
13. MacLennan DH, Philips MS. Malignant hyperthermia. Science. 1992;256:789-794.
14. Ørding H. Diagnosis of susceptibility to malignant hyrperthermia in man. Br J Anaesth. 1988;60:287-302.
15. Ellis FR, Clarke IMC, Mogill M, et al. Evaluation of creatinine phosphokinase in screening patients for malignant hyperthermia. BMJ. 1975;3:511-513.
16. Ranklev E, Henriksson K, Fletcher R, et al. Clinical and muscle biopsy findings in malignant hyperthermia susceptibility. Acta Neurol Scand. 1986;74: 452-459.
17. McPherson E, Taylor CA. The genetics of malignant hyperthermia: evidence for heterogeneity. Am J Med Genet. 1982;11:273-285.
18. Amaranath L, Lavin TJ, Trusso RA, et al. Evaluation of creatinine [sic] phosphokinase screening as a predictor of malignant hyperthermia. Br J Anaesth. 1983;55:531-533.
19. Ørding H, for the European Malignant Hyperthermia Group. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. Acta Anaesthesiol Scand. 1997;41:955-966.
20. Iaizzo PA, Lehmann-Horn F. Anesthetic complications in muscle disorders. Anesthesiology. 1995;82: 1093-1096.
21. Heytens L, Martin JJ, van der Kleft E, et al. In vitro contracture tests in patients with various neuromuscular diseases. Br J Anaesth. 1992;68:72-75.
22. Anetseder M, Hager M, Müller CR, et al. Diagnosis of susceptibility to malignant hyperthermia by use of a metabolic test. Lancet. 2002;359:1579-1580.